Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland
- 1 January 2001
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (1), 59-75
- https://doi.org/10.2165/00019053-200119001-00005
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Healthcare Resource Utilisation and Costs of Treating NSAID-Associated Gastrointestinal ToxicityPharmacoEconomics, 2001
- The Burden of Arthritis and Nonsteroidal Anti-Inflammatory TreatmentPharmacoEconomics, 2001
- Primary gastroduodenal prophylaxis with omeprazole for non‐steroidal anti‐inflammatory drug usersAlimentary Pharmacology & Therapeutics, 1998
- Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcersDigestive Diseases and Sciences, 1995
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- Effect of Cimetidine on Gastrointestinal Symptoms in Patients Taking Nonsteroidal Anti-inflammatory Drugs:A large Double-blind Placebo Controlled StudyScandinavian Journal of Rheumatology, 1994
- Efficacy of 12 Months' Misoprostol as Prophylaxis against IMSAID-induced Gastric Ulcers:A placebo-controlled trialScandinavian Journal of Rheumatology, 1994
- Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis.Annals Of The Rheumatic Diseases, 1993
- THE GASTRODUODENAL SAFETY AND EFFICACY OF THE FIXED COMBINATION OF DICLOFENAC AND MISOPROSTOL IN THE TREATMENT OF OSTEOARTHRITISRheumatology, 1992
- A Doubleblind Comparison of the Gastroduodenal Safety and Efficacy of Diclofenac and a Fixed Dose Combination of Diclofenac and Misoprostol in the Treatment of Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1992